JP7089141B2 - 新規なｊａｋ１選択的阻害剤およびその使用 - Google Patents

新規なｊａｋ１選択的阻害剤およびその使用 Download PDF

Info

Publication number
JP7089141B2
JP7089141B2 JP2019517991A JP2019517991A JP7089141B2 JP 7089141 B2 JP7089141 B2 JP 7089141B2 JP 2019517991 A JP2019517991 A JP 2019517991A JP 2019517991 A JP2019517991 A JP 2019517991A JP 7089141 B2 JP7089141 B2 JP 7089141B2
Authority
JP
Japan
Prior art keywords
compound
nrr
formula
imidazole
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019517991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537559A5 (enExample
JP2019537559A (ja
Inventor
リアング，コングシン
Original Assignee
ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド filed Critical ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド
Publication of JP2019537559A publication Critical patent/JP2019537559A/ja
Publication of JP2019537559A5 publication Critical patent/JP2019537559A5/ja
Application granted granted Critical
Publication of JP7089141B2 publication Critical patent/JP7089141B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2019517991A 2016-10-03 2017-09-30 新規なｊａｋ１選択的阻害剤およびその使用 Active JP7089141B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403660P 2016-10-03 2016-10-03
US62/403,660 2016-10-03
PCT/US2017/054668 WO2018067422A1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2019537559A JP2019537559A (ja) 2019-12-26
JP2019537559A5 JP2019537559A5 (enExample) 2021-03-04
JP7089141B2 true JP7089141B2 (ja) 2022-06-22

Family

ID=61831161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019517991A Active JP7089141B2 (ja) 2016-10-03 2017-09-30 新規なｊａｋ１選択的阻害剤およびその使用

Country Status (19)

Country Link
US (3) USRE50799E1 (enExample)
EP (1) EP3509591B1 (enExample)
JP (1) JP7089141B2 (enExample)
KR (1) KR102399848B1 (enExample)
CN (2) CN108366994B (enExample)
AU (3) AU2017339417C1 (enExample)
DK (1) DK3509591T3 (enExample)
EA (1) EA201990523A1 (enExample)
ES (1) ES2901216T3 (enExample)
HK (1) HK1253040A1 (enExample)
HR (1) HRP20211965T1 (enExample)
HU (1) HUE058120T2 (enExample)
IL (3) IL265358B (enExample)
MX (1) MX390005B (enExample)
NZ (1) NZ751284A (enExample)
PL (1) PL3509591T3 (enExample)
PT (1) PT3509591T (enExample)
RS (1) RS62695B1 (enExample)
WO (1) WO2018067422A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366994B (zh) 2016-10-03 2021-10-01 杭州高光制药有限公司 新型Jak1选择性抑制剂及其用途
AU2018208516B2 (en) 2017-01-11 2021-07-08 Aqilion Ab Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
IL282643B2 (en) 2018-10-31 2025-08-01 Incyte Corp A selective jak1 inhibitor for use in a method of treating hematological disease
IL285999B2 (en) * 2019-03-05 2026-01-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
KR102785014B1 (ko) * 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
KR20250140639A (ko) * 2019-06-06 2025-09-25 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 다형성 물질 및 염의 다형성 물질
US20230192617A1 (en) 2020-05-19 2023-06-22 Bayer Cropscience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
WO2021249995A1 (en) 2020-06-10 2021-12-16 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
US20240307396A1 (en) * 2021-06-07 2024-09-19 The Regents Of The University Of California Compositions and methods for treating celiac disease
JP2024543198A (ja) * 2021-09-13 2024-11-19 ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド 中枢神経障害を治療する方法
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
WO2025224600A1 (en) * 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection
WO2025248468A1 (en) 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)
WO2026002028A1 (zh) * 2024-06-26 2026-01-02 杭州多域生物技术有限公司 稠杂芳环类化合物、其药物组合物及其应用
WO2026032213A1 (zh) * 2024-08-08 2026-02-12 普罗思特(南京)生物科技有限公司 取代的三环衍生物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535288A (ja) 2012-11-01 2015-12-10 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983092A (en) 1975-01-20 1976-09-28 Ciba-Geigy Corporation Phenylindane diamine mixture and epoxy resin therewith
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
EP1720855A4 (en) 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
CN101282974A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的咪唑并吡啶衍生物
CN101238186B (zh) 2005-08-11 2012-10-24 3M创新有限公司 作为金属基底涂层的互穿聚合物网络及其制造方法
WO2007039146A1 (en) 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
US7879968B2 (en) 2006-10-17 2011-02-01 Taylor Made Golf Company, Inc. Polymer compositions and golf balls with reduced yellowing
US20100280151A1 (en) 2009-05-04 2010-11-04 Toray Industries, Inc. Toughened fiber reinforced polymer composite with core-shell particles
WO2011041399A2 (en) * 2009-09-29 2011-04-07 Tyrogenex, Inc. Pi3k (delta) selective inhibitors
WO2011138657A1 (en) 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
BR112013008240A2 (pt) * 2010-10-08 2017-12-12 Abbvie Inc compostos de furo [3-2-d] pirimidina
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
PH12013502670A1 (en) * 2011-08-12 2016-07-29 Nissan Chemical Ind Ltd Tricyclic heterocyclic compounds and jak inhibitors
TW201319063A (zh) 2011-10-04 2013-05-16 Yakult Honsha Kk 以四氫噻唑衍生物或其鹽為有效成分之醫藥品
CN103450125B (zh) 2013-07-18 2016-01-13 嘉兴中科化学有限公司 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法
CA2926361A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
JP2017514832A (ja) 2014-04-30 2017-06-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ１抑制剤を調製する方法及びその新しい形態
EP2940022B1 (en) 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN105418620B (zh) 2014-09-23 2018-05-04 天津药明康德新药开发有限公司 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法
WO2016100349A2 (en) 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN106432232A (zh) 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
CN108366994B (zh) * 2016-10-03 2021-10-01 杭州高光制药有限公司 新型Jak1选择性抑制剂及其用途
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
CN107216334A (zh) 2017-06-29 2017-09-29 上海吉尔多肽有限公司 一种6‑氯呋喃[3,2‑b]吡啶的合成方法
KR20250140639A (ko) 2019-06-06 2025-09-25 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 다형성 물질 및 염의 다형성 물질
KR102803409B1 (ko) 2019-06-06 2025-05-07 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로서의 2,4,6-삼치환된 피리미딘 화합물
KR102785014B1 (ko) 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
CN114213424B (zh) 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535288A (ja) 2012-11-01 2015-12-10 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Organic Chemistry of Drug Design and Drug Action ，2nd Edition，2004年，pp.29-34

Also Published As

Publication number Publication date
BR112019005969A2 (pt) 2019-06-18
IL291267B2 (en) 2023-05-01
HRP20211965T1 (hr) 2022-03-18
HUE058120T2 (hu) 2022-07-28
IL291265A (en) 2022-05-01
WO2018067422A1 (en) 2018-04-12
IL291265B2 (en) 2023-05-01
PL3509591T3 (pl) 2022-01-31
CN113214278A (zh) 2021-08-06
IL291267A (en) 2022-05-01
CN108366994A (zh) 2018-08-03
JP2019537559A (ja) 2019-12-26
USRE49834E1 (en) 2024-02-13
US10738060B2 (en) 2020-08-11
PT3509591T (pt) 2021-12-27
EP3509591B1 (en) 2021-11-17
AU2017339417B2 (en) 2021-11-18
AU2022201061B2 (en) 2023-03-16
KR102399848B1 (ko) 2022-05-19
HK1253040A1 (zh) 2019-06-06
US20190256523A1 (en) 2019-08-22
RS62695B1 (sr) 2022-01-31
CN113214278B (zh) 2022-10-28
IL291265B1 (en) 2023-01-01
EA201990523A1 (ru) 2019-10-31
AU2017339417A1 (en) 2019-03-28
AU2022201061A1 (en) 2022-03-10
EP3509591A4 (en) 2020-03-25
IL265358A (en) 2019-05-30
NZ751284A (en) 2022-09-30
CN108366994B (zh) 2021-10-01
AU2017339417C1 (en) 2022-06-02
DK3509591T3 (da) 2021-12-20
USRE50799E1 (en) 2026-02-17
AU2022201058B2 (en) 2023-03-16
IL265358B (en) 2022-04-01
AU2022201058A1 (en) 2022-03-10
ES2901216T3 (es) 2022-03-21
IL291267B1 (en) 2023-01-01
MX390005B (es) 2025-03-20
CA3039178A1 (en) 2018-04-12
MX2019003649A (es) 2019-08-14
EP3509591A1 (en) 2019-07-17
KR20190057069A (ko) 2019-05-27

Similar Documents

Publication Publication Date Title
JP7089141B2 (ja) 新規なｊａｋ１選択的阻害剤およびその使用
JP7248256B2 (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
EP3555097B1 (en) Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
KR102181365B1 (ko) 단백질 키나아제 억제제로서 새로운 피롤로피리미딘 화합물
EP4520329A2 (en) Treatment of respiratory diseases with amino acid compounds
US20190367490A1 (en) Jak1 selective inhibitors
AU2021389180A9 (en) Heteroaryl carboxamide compound
TW202304880A (zh) Ｎ２－苯基嘧啶－２，４－二胺化合物及其製備方法及使用方法
CN108419436B (zh) 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
CA3039178C (en) Novel jak1 selective inhibitors and uses thereof
HK40047523B (en) Novel jak1 selective inhibitors and uses thereof
HK40047523A (en) Novel jak1 selective inhibitors and uses thereof
EA040948B1 (ru) Селективные ингибиторы jak1 и их применение
HK40004735B (en) Novel jak1 selective inhibitors and uses thereof
BR112019005969B1 (pt) Inibidores seletivos de jak1 e usos dos mesmos
JP2025163283A (ja) ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４，４－ジメチルペンタ－２－エンニトリルの結晶形
HK40098388A (en) Jak1 selective inhibitors
EA047776B1 (ru) Соединение гетероарилкарбоксамида
HK40065050A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK40014753A (en) Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
HK40014753B (en) Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210119

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220426

R150 Certificate of patent or registration of utility model

Ref document number: 7089141

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250